[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100580356":3},{"organization":4,"outcomesModule":7,"designInfo":22,"detailedDescription":21,"studyPopulation":21,"armGroups":28,"interventions":46,"overallOfficials":21,"centralContacts":70,"locations":77,"responsibleParty":280,"collaborators":21,"id":282,"slug":283,"hasResults":284,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":21,"eligibilityCriteria":288,"healthyVolunteers":284,"sex":289,"minAge":290,"maxAge":291,"enrollmentInfo":292,"targetDuration":21,"studyType":295,"phases":296,"briefSummary":298,"conditions":299,"keywords":301,"overallStatus":80,"whyStopped":21,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":317},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":21},[9],{"measure":10,"description":11,"timeFrame":12},"Safety and tolerability of VTX2735","Incidence of adverse events (AEs), serious adverse events (SAEs), and AEs leading to study treatment discontinuation","Day 1 of treatment period through study completion, up to 26 weeks",[14,18],{"measure":15,"description":16,"timeFrame":17},"Effect of VTX2735 on pericardial pain","Change from baseline in Numeric Pain Rating Scale (NRS) over time through Week 6","Day 1 of treatment period to Week 6 of treatment period",{"measure":19,"description":20,"timeFrame":17},"Effect of VTX2735 on inflammation","Change from baseline in High-Sensitivity C-Reactive Protein (hs-CRP) over time through Week 6",null,{"allocation":23,"interventionModel":24,"interventionModelDescription":21,"primaryPurpose":25,"observationalModel":21,"timePerspective":21,"maskingInfo":26},"NON_RANDOMIZED","PARALLEL","TREATMENT",{"masking":27,"maskingDescription":21,"whoMasked":21},"NONE",[29,34,37,40,43],{"label":30,"type":31,"description":21,"interventionNames":32},"Cohort A","EXPERIMENTAL",[33],"Drug: VTX2735",{"label":35,"type":31,"description":21,"interventionNames":36},"Cohort B Treatment Group B1",[33],{"label":38,"type":31,"description":21,"interventionNames":39},"Cohort B Treatment Group B2",[33],{"label":41,"type":31,"description":21,"interventionNames":42},"Cohort C Treatment Group C1",[33],{"label":44,"type":31,"description":21,"interventionNames":45},"Cohort C Treatment Group C2",[33],[47,54,58,62,66],{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":52},"DRUG","VTX2735","Dose A, Daily",[30],[53],"LY5625574",{"type":48,"name":49,"description":55,"armGroupLabels":56,"otherNames":57},"Dose B, Daily",[30,35,41,44],[53],{"type":48,"name":49,"description":59,"armGroupLabels":60,"otherNames":61},"Dose C, Daily",[38],[53],{"type":48,"name":49,"description":63,"armGroupLabels":64,"otherNames":65},"Dose D, Daily",[41],[53],{"type":48,"name":49,"description":67,"armGroupLabels":68,"otherNames":69},"Dose E, Daily",[44],[53],[71],{"name":72,"role":73,"phone":74,"phoneExt":75,"email":76},"Ventyx Clinical Trial Contact","CONTACT","888-411-5176","ext 108","ClinicalTrials@ventyxbio.com",[78,92,101,111,121,131,145,154,164,177,183,193,203,213,218,228,239,248,260,269],{"facility":79,"status":80,"city":81,"state":82,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":91,"contacts":21},"Site Location #840023","RECRUITING","La Jolla","California","92037","United States","US",{"type":87,"coordinates":88},"Point",[89,90],-117.2742,32.84727,{"lat":90,"lon":89},{"facility":93,"status":80,"city":94,"state":82,"zip":95,"country":84,"countryCode":85,"cosmosGeoPoint":96,"geoPoint":100,"contacts":21},"Local Site #840014","Orange","92868",{"type":87,"coordinates":97},[98,99],-117.85311,33.78779,{"lat":99,"lon":98},{"facility":102,"status":80,"city":103,"state":104,"zip":105,"country":84,"countryCode":85,"cosmosGeoPoint":106,"geoPoint":110,"contacts":21},"Local Site #840016","Saint Augustine","Florida","32086",{"type":87,"coordinates":107},[108,109],-81.31452,29.89469,{"lat":109,"lon":108},{"facility":112,"status":80,"city":113,"state":114,"zip":115,"country":84,"countryCode":85,"cosmosGeoPoint":116,"geoPoint":120,"contacts":21},"Local Site #840008","Chicago","Illinois","60611",{"type":87,"coordinates":117},[118,119],-87.65005,41.85003,{"lat":119,"lon":118},{"facility":122,"status":80,"city":123,"state":124,"zip":125,"country":84,"countryCode":85,"cosmosGeoPoint":126,"geoPoint":130,"contacts":21},"Local Site #840010","Boston","Massachusetts","02114",{"type":87,"coordinates":127},[128,129],-71.05977,42.35843,{"lat":129,"lon":128},{"facility":132,"status":80,"city":133,"state":134,"zip":135,"country":84,"countryCode":85,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Local Site #840005","Rochester","Minnesota","55905-0002",{"type":87,"coordinates":137},[138,139],-92.4699,44.02163,{"lat":139,"lon":138},[142],{"name":143,"role":144,"phone":21,"phoneExt":21,"email":21},"Sushil Luis","PRINCIPAL_INVESTIGATOR",{"facility":146,"status":80,"city":147,"state":147,"zip":148,"country":84,"countryCode":85,"cosmosGeoPoint":149,"geoPoint":153,"contacts":21},"Local Site #840020","New York","10032",{"type":87,"coordinates":150},[151,152],-74.00597,40.71427,{"lat":152,"lon":151},{"facility":155,"status":80,"city":156,"state":157,"zip":158,"country":84,"countryCode":85,"cosmosGeoPoint":159,"geoPoint":163,"contacts":21},"Local Site #840017","Cleveland","Ohio","44195",{"type":87,"coordinates":160},[161,162],-81.69541,41.4995,{"lat":162,"lon":161},{"facility":165,"status":80,"city":166,"state":167,"zip":168,"country":84,"countryCode":85,"cosmosGeoPoint":169,"geoPoint":173,"contacts":174},"Local Site #840019","Houston","Texas","77030",{"type":87,"coordinates":170},[171,172],-95.36327,29.76328,{"lat":172,"lon":171},[175],{"name":176,"role":144,"phone":21,"phoneExt":21,"email":21},"Maan Malahfji",{"facility":178,"status":80,"city":166,"state":167,"zip":179,"country":84,"countryCode":85,"cosmosGeoPoint":180,"geoPoint":182,"contacts":21},"Local Site #840001","77034",{"type":87,"coordinates":181},[171,172],{"lat":172,"lon":171},{"facility":184,"status":80,"city":185,"state":186,"zip":187,"country":84,"countryCode":85,"cosmosGeoPoint":188,"geoPoint":192,"contacts":21},"Local Site #840013","Salt Lake City","Utah","84132",{"type":87,"coordinates":189},[190,191],-111.89105,40.76078,{"lat":191,"lon":190},{"facility":194,"status":80,"city":195,"state":196,"zip":197,"country":84,"countryCode":85,"cosmosGeoPoint":198,"geoPoint":202,"contacts":21},"Local Site #840022","Burlington","Vermont","05401",{"type":87,"coordinates":199},[200,201],-73.21207,44.47588,{"lat":201,"lon":200},{"facility":204,"status":80,"city":205,"state":206,"zip":207,"country":84,"countryCode":85,"cosmosGeoPoint":208,"geoPoint":212,"contacts":21},"Local Site #840004","Richmond","Virginia","23298",{"type":87,"coordinates":209},[210,211],-77.46026,37.55376,{"lat":211,"lon":210},{"facility":214,"status":80,"city":205,"state":206,"zip":207,"country":84,"countryCode":85,"cosmosGeoPoint":215,"geoPoint":217,"contacts":21},"Local Site #840018",{"type":87,"coordinates":216},[210,211],{"lat":211,"lon":210},{"facility":219,"status":80,"city":220,"state":221,"zip":222,"country":84,"countryCode":85,"cosmosGeoPoint":223,"geoPoint":227,"contacts":21},"Local Site #840021","Seattle","Washington","98105",{"type":87,"coordinates":224},[225,226],-122.33207,47.60621,{"lat":226,"lon":225},{"facility":229,"status":80,"city":230,"state":21,"zip":231,"country":232,"countryCode":233,"cosmosGeoPoint":234,"geoPoint":238,"contacts":21},"Local Site #056001","Ghent","9000","Belgium","BE",{"type":87,"coordinates":235},[236,237],3.71667,51.05,{"lat":237,"lon":236},{"facility":240,"status":80,"city":241,"state":21,"zip":242,"country":232,"countryCode":233,"cosmosGeoPoint":243,"geoPoint":247,"contacts":21},"Local Site #056002","Leuven","3000",{"type":87,"coordinates":244},[245,246],4.70093,50.87959,{"lat":246,"lon":245},{"facility":249,"status":250,"city":251,"state":21,"zip":252,"country":253,"countryCode":254,"cosmosGeoPoint":255,"geoPoint":259,"contacts":21},"Local Site #840102","NOT_YET_RECRUITING","Montreal","H4A 3J1","Canada","CA",{"type":87,"coordinates":256},[257,258],-73.58781,45.50884,{"lat":258,"lon":257},{"facility":261,"status":80,"city":262,"state":21,"zip":263,"country":253,"countryCode":254,"cosmosGeoPoint":264,"geoPoint":268,"contacts":21},"Local Site #840101","Ottawa","K1Y 4S7",{"type":87,"coordinates":265},[266,267],-75.69812,45.41117,{"lat":267,"lon":266},{"facility":270,"status":250,"city":271,"state":21,"zip":272,"country":273,"countryCode":274,"cosmosGeoPoint":275,"geoPoint":279,"contacts":21},"Local Site #300001","Athens","11527","Greece","GR",{"type":87,"coordinates":276},[277,278],23.72784,37.98376,{"lat":278,"lon":277},{"type":281,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100580356","phase-2-an-open-label-pilot-study-of-vtx2735-in-recurrent-pericarditis-100580356",false,"NCT06836232","An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis","A Phase 2a, Open-Label Pilot Study to Evaluate the Safety\u002FTolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants With Recurrent Pericarditis","Inclusion Criteria:\n\n* Participants are male or female ≥ 18 years up to ≤ 75 years of age.\n* Capable of giving signed informed consent and able to comply with the protocol\n* Previously had an index (first) episode of pericarditis which met the criteria for an acute pericarditis event\n* Ongoing symptomatic episode of pericarditis, or may have an episode of recurrent pericarditis in the next 4 weeks.\n* CRP by local laboratory assessment prior to first dose of study treatment (participants with CRP ≤ 10 mg\u002FL must be receiving corticosteroid treatment for RP and have evidence of pericardial inflammation)\n* Pericarditis pain score ≥ 4 based on the 11-point NRS.\n* Stable doses of NSAIDs, colchicine, and\u002For oral corticosteroids (if receiving these treatments)\n\nExclusion Criteria:\n\n* Current or prior diagnosis of pericarditis that is secondary to specific prohibited causes, including but not limited to tuberculosis, blunt trauma, tumor, myocarditis, or systemic autoimmune diseases.\n* History of clinically significant immunosuppressive disorder, autoimmune\u002Fautoinflammatory disorder, or primary or secondary immunodeficiency.\n* Clinically important history of a medical disorder that would compromise safety or data quality, per the Investigator's judgment.","ALL","18 Years","75 Years",{"count":293,"type":294},50,"ESTIMATED","INTERVENTIONAL",[297],"PHASE2","This is a study to understand if taking VTX2735 is safe and effective in participants diagnosed with Recurrent Pericarditis (RP).\n\nCohort A will include approximately 10 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose A\n* A 7-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose A\n* An 11-week Once Daily Treatment Period (if a participant meets criteria for this treatment period) - participant receives VTX2735 Dose B\n* A 14-day Follow-Up Period\n\nCohort B will include approximately 20 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose B or C\n* An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B or C\n* A 14-day Follow-Up Period\n\nCohort C will include approximately 20 participants and will consist of the following:\n\n* A 30-day Screening Period (to see if a participant qualifies for the study)\n* A 6-week Open Label Treatment Period - participant receives VTX2735 Dose D or E, and B\n* An 18-week Extension Treatment Period (if a participant meets criteria for extension treatment) - participant receives VTX2735 Dose B\n* A 14-day Follow-Up Period",[300],"Recurrent Pericarditis",[302,303,300,49,304,305,306],"Ventyx","Zomagen","NLRP3 Inhibitor","NLRP3","Inflammasome","2026-10-08",{"date":309,"type":310},"2026-10-09","ACTUAL",{"date":312,"type":310},"2025-01-28",{"date":314,"type":294},"2027-10",{"name":316,"class":6},"Zomagen Biosciences Ltd.",20]